### PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases  
**Manuscript NO:** 75439  
**Title:** Occurrence of MYD88 65P and CD79B Mutations in Diffuse Large B Cell Lymphoma with Bone Marrow Infiltration: A case report  
**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed  
**Peer-review model:** Single blind  
**Reviewer’s code:** 03853274  
**Position:** Peer Reviewer  
**Academic degree:** MD  
**Professional title:** Academic Fellow  
**Reviewer’s Country/Territory:** Turkey  
**Author’s Country/Territory:** China  
**Manuscript submission date:** 2022-02-08  
**Reviewer chosen by:** AI Technique  
**Reviewer accepted review:** 2022-03-21 12:00  
**Reviewer performed review:** 2022-03-29 08:43  
**Review time:** 7 Days and 20 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>Yes</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS

Abstract What does the authors mean with MCD subtype of DLBCL? Case Presentation Does this patient had splenomegaly? Did the author performed a FDG PET CT for a DLBCL which transformed from an indolent lymphoma? I have read carefully the manuscript. But I think the manuscript lacks novelty. I do not think it is an interesting study to publish.
PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 75439

Title: Occurrence of MYD88 65P and CD79B Mutations in Diffuse Large B Cell Lymphoma with Bone Marrow Infiltration: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 01551432

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Doctor

Reviewer’s Country/Territory: Japan

Author’s Country/Territory: China

Manuscript submission date: 2022-02-08

Reviewer chosen by: Xin Liu

Reviewer accepted review: 2022-04-12 09:51

Reviewer performed review: 2022-04-16 11:19

Review time: 4 Days and 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td></td>
<td>[ ] Grade E: Do not publish</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ ] Grade A: Priority publishing</th>
<th>[Y] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[ ] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Minor revision</td>
<td>[Y] Major revision</td>
</tr>
</tbody>
</table>

| Re-review          | [Y] Yes | [ ] No |
SPECIFIC COMMENTS TO AUTHORS
Dear authors, Thank you for submitting your manuscript entitled, "Occurrence of MYD88L265P and CD79B Mutations in Diffuse Large B Cell Lymphoma with Bone Marrow Infiltration: case report" in WJCC. The manuscript is well written and carefully described, and the topics is interesting. However, several major criticisms should be addressed as below. Major 1. Line 120; Please add new figure(s) on the MYD88L265P and CD79B mutation, and fully explain what kind of mutation was specifically. For example, add the new figure on the result of direct sequencing, and so on. 2. Discussion; Search for and review similar cases that have been reported to date, and add a new Table on the summary of these cases. 3. Discussion; Please add a new schematic figure(s) on where and how it affected the transformation from WM to DLBCL, or the redundant long description of characters only explanation. The present descriptions is difficult to understand for WJCC readers, I think. Please add new schematic figures on NF-kB signaling pathway in the ABC subtype (line138), CD79B-dependent BCR activation pathway (line152), oncogene signaling pathway (line190) and explain it clearly and concisely. 4. Line183; I think figure 5. is unnecessary. Please reconsider it. If necessary, please check whether the source can be posted and indicate whether or not it has been partially modified. 5. After modifying them as below accordingly, please reconsider the validity of the contents of Discussion.
Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 75439

Title: Occurrence of MYD88 65P and CD79B Mutations in Diffuse Large B Cell Lymphoma with Bone Marrow Infiltration: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 01551432

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Doctor

Reviewer’s Country/Territory: Japan

Author’s Country/Territory: China

Manuscript submission date: 2022-02-08

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2022-05-27 23:52

Reviewer performed review: 2022-05-28 04:49

Review time: 4 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>Peer-Review: Anonymous</td>
<td>Anonymous</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


SPECIFIC COMMENTS TO AUTHORS

Dear Authors, Thank you for resubmitting your revised manuscript entitled, "Occurrence of MYD88L265P and CD79B Mutations in Diffuse Large B Cell Lymphoma with Bone Marrow Infiltration: A case report". The manuscript has been almost properly revised accordingly, however, just one minor criticism should be addressed as below. Minor) 1. See, for example, Table.1 in a recently published paper, Chun-Yan Weng, et al. World J Clin Cases. May 26, 2022; 10 (15): 4971-4984. Please create a new table for each item such as age, gender, histological type, staging, treatment method, clinical course, outcome, and so on. Instead, delete your Table in revised manuscript.